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Background
A significant effect of Omalizumab treatment on bron-
chial remodeling modulation(reduction of Reticular
Basal Membrane-RBM- thickening) by means of histolo-
gical evaluation of bronchial biopsies was documented
after therapy (Riccio et al. 2012). But we surprisingly
found two groups , Responders-R (reduction of tickening
of RBM) and Non Responders-NR (increasing or stable
RBM). We then applied the proteomic analysis to the
bronchial specimens. We used MudPIT (Multidimensional
Protein Identification Technology) proteomic approach, a
highthroughput methodology that allows the identification
of hundreds/thousands of proteins for a single complex
sample, evaluation of differential abundance, characteri-
zation of involved molecular pathways and sub-typing
diseases (Brambilla et al., 2012).
Methods
Eight patients were studied (7 non smoker; 3 females;
range of age 40-62 years; mean age 47.0±9.7sd;mean
BMI 23.8±3.1sd; mean total plasma IgE 309.4 IU/l
±218.2sd; mean FEV1 56.2%pred±14.5sd; ACT score
11.1±2.9sd) suffering from severe persistent atopic
asthma treated by Omalizumab for 12 months.
The identificationof the proteins (over 800) obtained
by MudPIT plus the Hierarchical clustering identified
some possible markers, including periostin. The identified
proteins were plotted into the interactomic networks by
means of Cytoscape software and its plug-in, permitting to
identify the main metabolic clusters involved in the NRvs
R differentiation.
Results
The major differences between R and NR were detected
in the Extra Cellular Matrix group of proteins. Among
them, Galectin-3 (Gal-3), a IgE binding protein. Gal-3 is
a regulatory molecule acting at variuos stages from
acute to chronic inflammation and tissue fibrogenesis.
It was able to define the two groups, being present in
all the R patients and absent in NR ones. These data
were confirmed by immunochemistry on those same
biopsies.
Conclusions
Galectin 3 can be considered a reliable biomarker to pre-
dict modulation of airways remodeling in severe asthma
patients treated with omalizumab.
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